NHDL, a recombinant V(L)/V(H) hybrid antibody control for IgG2/4 antibodies

The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produc...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:MAbs
Auteurs principaux: Lau, Corinna, McAdam, Martin Berner, Bergseth, Grethe, Grevys, Algirdas, Bruun, Jack Ansgar, Ludviksen, Judith Krey, Fure, Hilde, Espevik, Terje, Moen, Anders, Andersen, Jan Terje, Mollnes, Tom Eirik
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2019
Sujets:
Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6927768/
https://ncbi.nlm.nih.gov/pubmed/31671278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1686319
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires